faculty

Publications

Home / Publications / "Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial"

"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial"

Groups and Associations Guy Young 1, Alok Srivastava 2, Kaan Kavakli 3, Cecil Ross 4, Jameela Sathar 5, Chur-Woo You 6, Huyen Tran 7, Jing Sun 8, Runhui Wu 9, Stacey Poloskey 10, Zhiying Qiu 11, Salim Kichou 12, Shauna Andersson 13, Baisong Mei 13, Savita Rangarajan 14
Clinical Trial 2023

Abstract

Background: Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia B, irrespective of inhibitor status. We evaluated the efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors.